Not stated (corporate presentation filed with Item 2.02 and Item
Filed Nov 10, 2026No results table was filed. The only reported financial figure is cash, cash equivalents, investments and restricted cash of $108.8M at 6/30/2026, with runway stated as into 2027.
The filing describes clinical progress: PM577a and PM647 are in or cleared for Phase 1/2 trials with initial data anticipated in 2027, and a BLA for PM359 in CGD is planned for the first half of 2027. It reports no revenue, operating expense, net loss or EPS figures, and states cash runway into 2027 against $108.8M of cash, cash equivalents, investments and restricted cash at 6/30/2026.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Cash, cash equivalents, investments and restricted cash (as of 6/30/2026)other | $108.8M | – | – |
| BMS collaboration upfront payment (including $55M equity investment)other | $110M | – | – |
| BMS collaboration potential milestonesother | >$3.5 billion | – | – |
What drove it
- Wilson disease: PM577a CTA and IND cleared, clinical trial initiated, initial clinical data anticipated in 2027.
- AATD: PM647 IND cleared for Phase 1/2 trial, initial clinical data anticipated in 2027.
- CGD: PM359 Phase 1/2 data presented as proof-of-concept. The company plans to submit a BLA in the first half of 2027 following final FDA alignment.
- BMS collaboration (September 2024) for multiple ex vivo T cell products, with $110 million upfront (including $55M equity investment), more than $3.5 billion in potential milestones, and royalties on net sales.
- Patent estate: 10 U.S. and 21 ex-U.S. issued patents, as stated in the filing.
Concerns
- The filing states cash runway into 2027 against $108.8M of cash, cash equivalents, investments and restricted cash at 6/30/2026. The company's 2027 milestones include initial clinical data for PM577a and PM647 and the planned PM359 BLA submission.
- The forward-looking statements list the company's ability to continue as a going concern among the risks. The filing does not make a going-concern conclusion about its own financial statements.
- The milestones section lists the goal to secure multiple additional strategic partnerships to accelerate the pipeline and bolster financial resources.
What to watch
- Initial clinical data for PM577a (Wilson disease) and PM647 (AATD), both anticipated in 2027.
- Submission of the PM359 BLA for CGD, planned for the first half of 2027, following final FDA alignment.
- Additional strategic partnerships, which the company lists as a stated goal.
- Cash runway, which the company states extends into 2027.
- Progress on PM359 regulatory engagement with the FDA, referenced in the forward-looking statements.
Balance sheet and cash flow
- Cash, cash equivalents, investments and restricted cash of $108.8M for 6/30/2026, with cash runway into 2027, as stated on the slide titled Prime Medicine is Leading the Next Generation of Gene Editing.
- The filing states that the 2025 Cystic Fibrosis Foundation agreement provides expanded funding. The amounts printed are up to $15 million (January 2024 agreement) and up to $24 million (July 2025 agreement).
Analysis
The filing is a corporate presentation furnished under Item 2.02 and Item 8.01 of Form 8-K. It contains no income statement, revenue, operating expense, net loss, EPS, cash flow or guidance table, so this read cannot assess the reported period's financial results. The only financial figure for the company's own position is cash, cash equivalents, investments and restricted cash of $108.8M at 6/30/2026, and the company states cash runway into 2027. The presentation does not report a date for the period the presentation covers, so the figure should be read against that stated date.
The operational content is the core of the filing. The company reports that PM577a (Wilson disease) has its CTA and IND cleared and a clinical trial initiated, with initial data anticipated in 2027. PM647 (AATD) has its IND cleared, with initial data also anticipated in 2027. For CGD, the company presents Phase 1/2 PM359 data including neutrophil and platelet engraftment within 2-3 weeks and NADPH oxidase activity at approximately 3-4x the therapeutic threshold by day 30, and plans to submit a BLA in the first half of 2027 following final FDA alignment. The filing also states that no serious adverse events were attributed to PM359 and that no detectable off-target editing was observed in the lead programs. These are the company's own characterizations of preclinical and early clinical data and have not been validated by a third party in the document.
The BMS collaboration is presented with specific deal terms: $110 million upfront including a $55M equity investment, more than $3.5 billion in potential milestones (including $185 million in preclinical milestones, $1.2 billion in development milestones and more than $2.1 billion in commercial milestones), and royalties on net sales. Upfront and potential milestone amounts are deal terms and are not reported results for the period. The filing does not state how much of the upfront has been recognized in revenue, so no revenue figure can be attributed to the collaboration from this document.
Versus the prior period, the filing provides no comparison. There is no prior-year or prior-quarter figure for cash, no previous outlook and no segment data. The company's stated priorities for the period are a 2027 data readout for two liver programs, the CGD BLA submission and additional partnering. The company also lists securing strategic partnerships as a goal. Cash runway into 2027 and the planned 2027 milestones are both stated in the document, and the reader can compare them directly.
The items the reader should check against the full financial statements, which this presentation does not contain, are revenue and collaboration revenue recognition, operating expenses and net loss, and the period covered by the cash balance. The filing refers to a Form 10-K risk factors section for further detail on these matters.
Not in the filing
stated, not guessed- Fiscal period label and period end date for the results being presented. The filing gives only the presentation date (November 2026) and the cash balance date (6/30/2026).
- Total revenue, collaboration revenue and any revenue sub-lines.
- Research and development expense, general and administrative expense and total operating expenses, GAAP or otherwise.
- Operating loss, net loss and net loss per share (GAAP or non-GAAP).
- Prior-year and prior-quarter comparisons for cash, cash equivalents, investments and restricted cash.
- Operating cash flow, investing cash flow and free cash flow.
- Total assets, total liabilities and stockholders' equity.
- Debt balance and any financing activity.
- Share repurchases and dividends (none are mentioned in the filing).
- Guidance for revenue, operating expenses or cash use.
- Amount of BMS upfront revenue recognized in the period.
- Executive quotes: the filing contains no quoted statements by named executives.
- Prior-period outlook, so vs_prior_guidance cannot be assessed.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.